Do the Conventional Clinicopathologic Parameters Predict for Response and Survival in Head and Neck Cancer Patients Undergoing Neoadjuvant Chemotherapy?
Restricted accessResearch articleFirst published online November, 1996
Do the Conventional Clinicopathologic Parameters Predict for Response and Survival in Head and Neck Cancer Patients Undergoing Neoadjuvant Chemotherapy?
Neoadjuvant chemotherapy for head and neck carcinoma is still an important treatment modality. The prognostic value of patient and tumor parameters has been extensively evaluated in several trials, yielding mixed results. We report the prognostic factors emerging from a group of patients undergoing neoadjuvant chemotherapy.
Patients and methods
From April 1986 to June 1992, 149 consecutive patients received cisplatin-5-fluorouracil-based neoadjuvant chemotherapy. After four courses of chemotherapy, patients underwent local-regional treatment with surgery, radiation or both. A variety of patient and tumor characteristics were evaluated as predictors for response to chemotherapy and survival.
Results
The complete response, partial response and no response rates to NAC were 52%, 33% and 15%, respectively. No parameters predicted response to chemotherapy. At a maximum follow-up of 87 months, overall survival was 39% and disease-free survival was 49%. Variables shown to be predictors of survival in univariate analyses were age, performance status, histology, site, T, N, stage, and response to chemotherapy. Using the Cox regression analysis, only complete response to induction chemotherapy (P = 0.0006), performance status (P = 0.03), stage (P = 0.01), age (P = 0.03) and primary tumor site (P = 0.04) emerged as independent prognostic factors for survival.
Conclusions
Complete response to chemotherapy was confirmed as the strongest prognostic factor influencing survival. However, conventional clinicopathologic factors did not predict response, hence, potential prognostic biologic and molecular factors for response must be sought. At present, much effort must be made for the improvement of the complete response rate, which seems to be a requisite to prolong survival.
AdelsteinD., SharanV., EarleA., ShahA., VlastouC., Haria CarterS., DammC., HinesJ: Long-term results after chemoradiotherapy for locally confined squamous-cell head and neck cancer.Am. J. Clin. Oncol., 13: 440–447, 1990.
2.
AmerM.H., Al-SarrafM., VaitkeviciusV.K.: Factors that affect the response to chemotherapy and survival of patients with advanced head and neck cancer.Cancer, 43: 2202–2206, 1978.
3.
American Joint Committee on Cancer.Manual for staging of cancer (3rd edn.). J.B. Lippincott, Philadelphia, 1988.
4.
BachaudJ.M., DavidJ.M., ShubinskyR.E., PerinauD., BoussinG., SerranoE., De ForniM., PesseyJ.J., Daly-Sche-veitzerN.J.: Predictive factors of a complete response to and adverse effects of a CDDP-5FU combination as primary therapy for head and neck squamous carcinoma.J. Laryngol. Ot-ol., 107: 924–930, 1993.
5.
BakerS.R., MakuchR.W., WolfG.T.: Preoperative cisplatin and bleomycin therapy in head and neck squamous carcinoma. Prognostic factors for tumor response.Arch. Otolaryngol. Head Neck Surg., 107: 683–689, 1981.
6.
BerensonJ.R., YangJ., MickelR.A.: Frequent amplification of the bcl-1 locus in head and neck squamous cell carcinomas.Oncogene, 4: 1111–1116, 1989.
7.
BrachmanD.G., BeckettM., GravesD., HarafD., VokesE., WeichselbaumR.R.: p53 mutation does not correlate with radiosensivity in 24 head and neck cancer cell lines.Cancer Res., 53: 3667–3669, 1993.
8.
BrachmanD.G., GravesD., VokesE., DeckettM., HarafD., MontagA., DunphyE., MichR., YandellD., WeichselbaumR.R.: Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer.Cancer Res., 62: 4832–4836, 1992.
9.
CastilloI., GomezF., GuerreroR., SanchezP., LopezM., CuetoJ., Garcia-PucheJ.L.: Prognostic factors in head and neck cancer patients included in a program of neoadjuvant chemotherapy and clinical radiotherapy.In: Cancer treatment, an update, BanzetP., HollandJ.F., KhayatD., WeilM. (Eds.), pp. 248–250, Springer-Verlag, Paris, 1994.
10.
CognettiF., PinnaroP., RuggeriE.M., CarliniP., PerrinoA., ImpiombatoF.A., CalabresiF., ChielliM.G., GiannarelliD.: Prognostic factors for chemotherapy and survival using combination chemotherapy as initial treatment for advanced head and neck squamous cell cancer.J. Clin. Oncol., 7: 829–837, 1989.
11.
CoxD.R.: Regression models and life tables.J. Rev. Stat. Assoc., 53: 471–481, 1958.
12.
CoxD.R.: Analysis of binary data.Chapman & Hall, London, 1977.
13.
CravenJ.M., PavelicZ., StranbrookP.J., PavelicL., GapanyM., KelleyD.J., GapanyS., GluckmanJ.L.: Expression of c-erb-B2 gene in human head and neck carcinoma.Anticancer Res., 12: 2273–2276, 1992.
14.
CruzJ.J., FonsecaE., MuñozA., NietoA., GomezA., GarciaJ., MartinG., SanchezP., PanaderoA., GarciaM.J., DueñasG.A., GomezJ.L., PardalJ.L., SoriaP.: Induction chemotherapy with cisplatin, 5-fluorouracil and high-dose leucovorin for advanced head and neck cancer.J. Infusion Chemother., 5: 125–128, 1995.
15.
DassonvilleO., FormentoJ.L., FrancovalM., RamaioliA., SantiniJ., SchneiderM., DemardF., MilanoG.: Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer.J. Clin. Oncol., 12: 1873–1878, 1993.
16.
DavisR.K., StokerK., HarkerG., DavisK., GibbsF.A.Jr., HarnsbergerH.R., StevensM.H., ParkinJ.L., JohnsonL.P.: Prognostic indicators in head and neck cancer patients receiving combined therapy.Arch. Otolaryngol. Head Neck Surg., 115: 1443–1445, 1989.
17.
DimeryI.W., HongW.K.: Overview of combined modality therapies for head and neck cancer.J. Natl. Cancer Inst., 85: 95–111, 1993.
18.
DreyfussA.I., ClarkJ.R., WrightJ.E., NorrisC.M.Jr., BusseP.M., LucariniJ.W., FallenB.G., CaseyD., AndersenJ.W., KleinR., RosowskyA., MillerD., FreiE.III: Continuous infusion high-dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and neck.Ann. Intern. Med., 112: 167–172, 1990.
19.
EnsleyJ.: Molecular medicine - The forest, trees and leaves.Arch. Otolaryngol. Head Neck Surg., 119: 1173–1177, 1993.
20.
EnsleyJ.F., JacobsJ.R., WeaverA.: Correlation between response to cisplatin-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck.Cancer, 54: 811–814, 1984.
21.
EnsleyJ.F., MaciorowskiZ.: Clinical utility of flow cytometry in head and neck cancer.Semin. Oncol., 21: 330–339, 1994.
22.
EnsleyJ., MaciorowskiZ., PearA., PietrosekiewiczZ., AlonsoM., SarkrW.: The selection of patients for clinical trials with squamous cell carcinoma of the head and neck (SCCHN) based on the existence of pure DNA aneuploid tumors documented by multiparameter flow cytometry (Abst.).Proc. Am. Soc. Clin. Oncol., 12: 281, 1993.
23.
EnsleyJ.F., MaciorowskiZ., PietroszkiewiczZ., de BraudF., SakrW.: Methodology and clinical applications of cellular DNA content parameters determined by flow cytometry in squamous cell cancers of the head and neck.Cancer Treat. Res., 52: 225–242, 1990.
24.
ErvinT.J., ClarkJ.R., WeichselbaumR.R., FallenB.G., MillerD., FabianR.L., PosnerM.R., NorrisC.M., TuttleS.A.: An analysis of induction and adjuvant chemotherapy in the multidisciplinary treatment of squamous cell carcinoma of the head and neck.J. Clin. Oncol., 5: 10–20, 1987.
25.
FieldJ.K.: Oncogenes and tumor-suppressor genes in squamous cell carcinoma of the head and neck.Oral Oncol. Eur. J. Cancer, 61: 365–368, 1990.
26.
FonsecaE., CruzJ.J., GomezA., SanchezP., MartinG., SantosP., MuñozA., NietoA.: Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil both in continuous 96 hours infusion in the treatment of locally advanced head and neck cancer.Am. J. Clin. Oncol., 17: 6–9, 1994.
27.
FonsecaE., CruzJ.J., MartinG., DuenasA., GomezA., GarciaM.J., PanaderoA., SanchezP., GarciaJ., GarciaG.: Neoadjuvant chemotherapy in locally advanced head and neck cancer (Abst).Proc. Am. Soc. Clin. Oncol., 13: 284, 1994.
28.
ForastiereA.A., MetchB., SchulterD.E., EnsleyJ.F., HutchinsL.F., TriozziP., KishJ., McClureS., Von FeldtE., WilliamsonS.K., Von HoffD.D.: Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck.J. Clin. Oncol., 10: 1245–1251, 1992.
29.
FountzilasG., KasmididP., BeerM., ShridharK.S., BanisK., VritsiosA., DanniilidisJ.: Factors influencing complete response and survival in patients with head and neck cancer treated with platinum-based induction chemotherapy.Ann. Oncol., 3: 553–558, 1992.
30.
GouY.C., DeSantoL., OsetinskyG.V.: Prognostic implications of nuclear DNA content in head and neck cancer.Otolaryngol. Head Neck Surg., 100: 95–98, 1989.
31.
GreenbergB., AhmanF., GarewalH., KoopmanC., CouhardS., BerzesH., AlbertsD., ShimmO., SlymenD.: Neoadjuvant therapy for advanced head and neck cancer with allopurinol-modulated high-dose 5-fluorouracil and cisplatin: a phase I-II study.Cancer, 59: 1860–1865, 1987.
32.
HillB.T., PriceL.A.: Lack of survival advantage in patients with advanced squamous cell carcinomas of the oral cavity receiving neoadjuvant chemotherapy prior local therapy despite achieving an initial high clinical complete response rate.Am. J. Clin. Oncol., 17: 1–5, 1994.
33.
HillB.T., PriceL.A., MacRaeK.: Importance of primary site in assessing chemotherapy response and 7-year survival data in advanced squamous-cell carcinoma of the head and neck treated with initial combination chemotherapy without cisplatin.J. Clin. Oncol., 4: 1340–1347, 1986.
34.
JacobsC., LymanG., Velez-Garcfa, SridharK., KnightW., HochsterH., GoodnoughL., MortimerJ., EinhornL., SchacterL., CherngN., DaltonT., BurroughsJ., RozencweigM.: A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.J. Clin. Oncol., 10: 257–263, 1992.
35.
JanetF., CvitkovicE., PiekarskiJ.D., SigalR., ArmandJ.P., BensmaineA., LuboinskiB.: Correlation between nodal density in contrasted scans and response to cisplatin-based chemotherapy in head and neck squamous cell cancer: a prospective validation.Head Neck, 15: 222–229, 1993.
36.
JaulerryC., RodriguezJ., BruninF., JouveM., MosseriV., PointD., PontvertD., ValidireP., ZafraniB., BlaszkaB., As-selainB., PouillartP., BrugereJ.: Induction chemotherapy in advanced head and neck tumors: results of two randomized trials.Int. J. Radiat. Oncol. Biol. Phys., 23: 483–489, 1992.
37.
KearsleyJ.H., BrysonG., BattisttutaD., CollinsR.J.: Prognostic importance of cellular DNA content in head and neck squamous cell cancers. A comparison of retrospective and prospective series.Int. J. Cancer, 47: 31–37, 1991.
38.
KokalR.L., GardineK., SheibaniI.W., ZakI.W., BeattyJ.D., RiihimakiD.U., WagmanL.D., TerzJ.J.: Tumor DNA content as a prognostic indicator in squamous cell carcinoma of the head and neck region.J. Clin. Oncol., 7: 149, 1988.
39.
LydiattD.D., SavageH.E., ClaymanG.L., LiuF.J., SampleD., SchantzS.P.: Serologic determinants of survival in patients with head and neck cancer: validating a clinical prediction model.Laryngoscope, 103: 13–16, 1993.
40.
MaheE., FilleulA., SachwaldJ., MeeusL., BertrandF., Ber-lieJ., BanalA., ZojajiA., Tubiana-HulinM.: Retrospective study of 139 cases of epidermoid carcinoma of the upper respiratory and digestive tracts treated by induction chemotherapy with cisplatin-5FU. Influence of the results on the therapeutic protocol.Ann. Otolaryngol. Chir. Cervicofac., 109: 410–416, 1992.
41.
MarsoniS., ValsecchiM.G.: Prognostic factors analysis in clinical oncology: handle with care (Editorial).Ann. Oncol., 2: 245–247, 1991.
42.
MillerA.B., HoogstratenB., StaquetM., WinklerA.: Reporting results of cancer treatment.Cancer, 47: 207–214, 1981.
43.
NorusisM.J.: SPSSX: Statistical package for the social sciences plus.McGraw-Hill, New York, 1983.
44.
PennachioJ.L., HongW.K., ShapshayS., GillisT., VaughanC., BhutnaniR., UcmakliA., KatzA., BromerR., WilletB., StrongS.M.: Combination of cisplatin and bleomycin prior to surgery and/or radiotherapy compared with radiotherapy alone for the treatment of advanced squamous cell carcinoma of the head and neck.Cancer, 50: 2795–2799, 1982.
45.
PetoP., PikeM.C.: Conservation of the approximation (O-E) 2/E in log-rank test survival data on tumor incidence data.Biometrika, 29: 579–584, 1977.
46.
PintoH.A., JacobsC.: Chemotherapy for recurrent and metastatic head and neck cancer.Hematol. Oncol. Clin. North Am., 5: 687–686, 1991.
47.
RooneyM., KishJ., JacobsJ., KinzieJ., WeaverA., Crism-manJ., Al-SarrafM.: Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120 hours 5-FU infusion and cisplatin.Cancer, 55: 1123–1128, 1985.
48.
RuaS., CominoA., FrutteroA., CeraG., SemeriaC., Lanzil-lottaL., BoffettaP.: Relationship between histologic features, DNA flow cytometry and clinical behavior of squamous cell carcinomas of the larynx.Cancer, 67: 141–149, 1991.
49.
SantiniJ., FormentoJ.L., FrancovalM., MilanoG., SchneiderM., DassonvilleO., DemardF.: Characterization, quantification and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinoma.Head Neck, 13: 132–139, 1991.
50.
SchantzS.P., HarrisonL.B., HongW.K.: Cancer of the head and neck.In: Cancer: principles and practice of oncology, 4th Edn., De VitaV.T.Jr., HellmanS., RosenbergS.A. (Eds.), pp. 574–630, J.B. Lippincott, Philadelphia, 1993.
51.
SchantzS.P., SavageH.E., RaczT., LiuF.J., BrownB.V., RossenR.D., HongW.K.: Immunologic determinants of head and neck cancer response to induction chemotherapy.J. Clin. Oncol., 7: 857–864, 1989.
52.
SchullerD.E., WilsonH.E., SmithR.E., BatleyF., JamesA.: Preoperative reductive chemotherapy for locally advanced carcinoma of the oral cavity, oropharynx, and hypopharynx.Cancer, 51: 15–19, 1983.
53.
Sickle-SantanelloB.J., FarrarW.B., DobsonJ.L., O'TooleR.V., Keynani-RofagnaS.: Flow cytometry as a prognostic indicator in squamous cell carcinoma of the tongue.Am. J. Surg., 152: 393–395, 1986.
54.
The Department of Veterans Affairs Laryngeal Cancer Study Group.Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.N. Engl. J. Med., 324: 1685–1690, 1991.
55.
ToohillR.J., AndersonT., ByhardtR.W., CoxJ.D., DuncavageJ.D., GrossmanT.W., HassC.C., HassJ.S., HartzA.J., LibnochJ.A., MalinT.C., RitchP.S., WinsonJ.F.: Cisplatin and fluorouracil as neoadjuvant therapy in head and neck cancer.Arch. Otolaryngol. Head Neck Surg., 113: 758–761, 1987.
56.
TupchongL., BrodovskyH., RoseL., LowryL.D.: Phase I/II study of hyperfractionated chemoradiotherapy for advanced inoperable head and neck carcinoma (Abst.).Proc. Am. Soc. Clin. Oncol., 10: 207, 1991.
57.
VokesE.E., WeichselbaumR.R., RatainM.J., McEvillyJ.M., ErwinT.J., WenigB., BerezieinF., HarafD., SchilzkyR.L., KozloffM.F., PangeW.R.: PFL with escalating doses of interferon-alpha-2B as neoadjuvant chemotherapy for stage IV head and neck cancer. A clinical and pharmacological analysis (Abst.).Proc. Am. Soc. Clin. Oncol., 10: 208, 1991.
58.
WolfG.T., MakuchR.W., BakerS.R.: Predictive factors for tumor response to preoperative chemotherapy in patients with head and neck squamous carcinoma. The Head and Neck Contracts Program.Cancer, 54: 2896–2877, 1984.
